

Advanced Biosimilars-first Medical Preferred Drug List

Medicare Part B Step Therapy

The GlobalHealth Advanced Biosimilars-first Medical Preferred Drug List encourages utilization of clinically appropriate and lower net cost products within the following therapeutic drug classes. The GlobalHealth Advanced Biosimilars-first Medical Preferred Drug List applies to the listed products only and any other product may be available under a plan’s medical benefit.

The listed preferred products must be used first. An exception process is in place for specific circumstances that may warrant a need for a non-preferred product. For example, this step therapy requirement does not apply to plan’s members who are actively receiving treatment (i.e., members with a paid claim within the past 365 days) with non-preferred product on the GlobalHealth Advanced Biosimilars-first Medical Preferred Drug List.

<i>Drug Class</i>	<i>Non-Preferred Product(s)*</i>	<i>Preferred Product(s)</i>
<i>Alpha-1 Antitrypsin Deficiency</i>	Aralast Glassia	Prolastin-C Zemaira
<i>Antimetabolites</i>	Alimta Pemfexy	Pemetrexed
<i>Autoimmune Infused/Infliximab</i>	Infliximab Remicade Renflexis	Avsola Inflectra

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with GlobalHealth. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

Effective Date: 1/1/2024

Last Updated: 7/1/2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Autoimmune Infused/Other	Actemra Cimzia Ilumya Orencia Stelara	Entyvio Simponi Aria
Avastin/Biosimilars (Oncology)	Alymsys Avastin Vegzelma Zirabev	Mvasi
Botulinum Toxins	Botox Myobloc	Dysport Xeomin
Breast Cancer MAb	Perjeta	Phesgo
Complement Inhibitors (aHUS, gMG, PNH)		Soliris Ultomiris
Complement Inhibitors (NMOSD)	Uplizna	Soliris
Hematologic, Erythropoiesis – Stimulating Agents (ESA)	Epogen Mircera Procrit	Aranesp Retacrit

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with GlobalHealth. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber.

Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

Effective Date: 1/1/2024

Last Updated: 7/1/2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
<i>Hematologic, Neutropenia Colony Stimulating Factors – Long Acting</i>	Fylnetra Neulasta Nyvepria Rolvedon Stimufend Udenyca	Fulphila Ziextenzo
<i>Hematologic, Neutropenia Colony Stimulating Factors – Short Acting</i>	Granix Leukine Neupogen Nivestym Releuko	Zarxio
<i>Hematopoietic Agents- Iron</i>	Feraheme Injectafer Monoferric	Ferlecit Infed Sodium Ferric Gluconate Venofer
<i>Hemophilia Factor VIII- Recombinant</i>	Advate Afstyla Kogenate Novoeight Nuwiq Recombinate Xyntha Xyntha Solofuse	Kovaltry

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with GlobalHealth. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

Effective Date: 1/1/2024

Last Updated: 7/1/2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Hemophilia Factor IX-Recombinant		Alprolix Idelvion
Immune Globulin- IV	Asceniv Bivigam Gammagard Liquid Gammaplex Panzyga	Flebogamma Gammaked Gamunex-C Octagam Privigen
Immune Globulin- SC	Cutaquig Cuvitru HyQvia Xembify	Hizentra
Lysosomal Storage Disorders – Gaucher Disease	VPRIV	Cerezyme Elelyso
Mitotic Inhibitors	Abraxane	Docetaxel Paclitaxel
Multiple Myeloma Proteasome Inhibitors	Empliciti Kyprolis Sarclisa Velcade	Bortezomib
Multiple Sclerosis (Infused)	Briumvi Lemtrada	Ocrevus Tysabri
Osteoarthritis,	Euflexxa Gelsyn-3	Orthovisc Synvisc

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with GlobalHealth. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

Effective Date: 1/1/2024

Last Updated: 7/1/2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Viscosupplements – Multi Injection	GenVisc Hyalgan Hymovis Supartz FX Triluron TriVisc Visco-3	
Osteoarthritis, Viscosupplements – Single Injection	Gel-One Monovisc	Durolane Synvisc-One
Osteoporosis- Bone Density	Evenity	Prolia Zoledronic Acid
Osteoporosis- Hypercalcemia of Malignancy	Xgeva	Pamidronate Zoledronic Acid
PD1/L1 Immune Checkpoint Inhibitors - Basal Cell & Squamous Cell	Keytruda	Libtayo
PD1/L1 Immune Checkpoint Inhibitors - NSCLC	Imfinzi Keytruda Opdivo Tecentriq	Libtayo

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with GlobalHealth. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber.

Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

Effective Date: 1/1/2024

Last Updated: 7/1/2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
<i>Prostate Cancer – Luteinizing Hormone Releasing Hormone (LHRH) Agents</i>	Camcevi Lupron Depot Trelstar Zoladex	Eligard
<i>Prostate Cancer – Luteinizing Hormone Releasing Hormone (LHRH) Antagonists Agents</i>		Firmagon
<i>Retinal Disorders Agents- (ARMD) Age-Related Macular Degeneration</i>	Beovu Cimerli Eylea Lucentis Susvimo Vabysmo	Avastin Byooviz
<i>Rituximab</i>	Riabni Rituxan Rituxan Hycela	Ruxience Truxima
<i>Severe Asthma</i>	Cinqair Nucala Tezspire	Fasenra Xolair
<i>Somatostatin Analogues</i>	Signifor LAR Somatuline Depot	Lanreotide Acetate Sandostatin LAR Depot

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with GlobalHealth. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber.

Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.

Effective Date: 1/1/2024

Last Updated: 7/1/2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Trastuzumab	Herceptin Herceptin Hylecta Herzuma Ontruzant	Kanjinti Ogivri Trazimera

*Non-preferred product(s) are only available if process exception criteria are met. This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with GlobalHealth. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes. Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information.
Effective Date: 1/1/2024
Last Updated: 7/1/2024